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Abstract
Acylcarnitine accumulation has been linked to perturbations in
energy metabolism pathways. In this study, we demonstrate that
long-chain (LC) acylcarnitines are active metabolites involved in
the regulation of glucose metabolism in vivo. Single-dose adminis-
tration of palmitoylcarnitine (PC) in fed mice induced marked insu-
lin insensitivity, decreased glucose uptake in muscles, and
elevated blood glucose levels. Increase in the content of LC acylcar-
nitine induced insulin resistance by impairing Akt phosphorylation
at Ser473. The long-term administration of PC using slow-release
osmotic minipumps induced marked hyperinsulinemia, insulin
resistance, and glucose intolerance, suggesting that the permanent
accumulation of LC acylcarnitines can accelerate the progression
of insulin resistance. The decrease of acylcarnitine content signifi-
cantly improved glucose tolerance in a mouse model of diet-
induced glucose intolerance. In conclusion, we show that the
physiological increase in content of acylcarnitines ensures the tran-
sition from a fed to fasted state in order to limit glucose metabo-
lism in the fasted state. In the fed state, the inability of insulin to
inhibit LC acylcarnitine production induces disturbances in glucose
uptake and metabolism. The reduction of acylcarnitine content
could be an effective strategy to improve insulin sensitivity.
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Insulin resistance, as the main feature of type 2 diabetes,
involves inappropriate glucose metabolism. It has been sug-
gested that insulin resistance and disturbances in glucose
metabolism is induced by excessive fatty acid (FA) flux which
results in incomplete FA oxidation and the accumulation of
various lipid metabolites, including free FA, diacylglycerols,
ceramides, acyl-CoAs, and acylcarnitines. Among FA inter-
mediates linked to insulin resistance are long-chain (LC) acyl-
carnitines [1,2]. The CPT-1-catalyzed synthesis of LC acylcarni-
tines is an important step in LC FA uptake in mitochondria [3].
Generally, CPT-1 has been known only as a step in the mito-
chondrial FA oxidation, and the accumulation of LC acylcarni-
tines has been seen as marker of incomplete mitochondrial
metabolism of FA. However, taking into account the LC
acylcarnitine-induced effects on Akt phosphorylation [4,5], an
increase in LC acylcarnitine content could be considered as a
feedback inhibition mechanism of insulin action. In this way,
insulin- and AMPK-mediated regulation of CPT-1 activity
would have physiological meaning, and LC acylcarnitines
would emerge as active metabolites important for the regula-
tion of energy metabolism.
It has been determined that plasma and skeletal muscle
concentrations of LC acylcarnitines are modestly increased
among individuals with insulin resistance and type 2 diabetes
mellitus [6,7]. Recently, it was shown that during insulin stim-
ulation, plasma levels of LC acylcarnitines reflect age-related
metabolic dysfunction [8]. LC acylcarnitines are very active
and effectively inhibit pyruvate and lactate oxidation in mito-
chondria, thus, compromising glucose uptake and oxidation in
models of isolated mitochondria [9], cell culture [5], and iso-
lated heart tissue [9,10]. It was hypothesized that LC acylcarni-
tines ensure the inhibition of glucose metabolism in order to
avoid hypoglycemia and gain energy from unlimited lipid
stores [9]. Thus, considering LC acylcarnitines as important
players in metabolism, it is worthwhile to study their role in
the development of insulin resistance.
In this study, we used both LC acylcarnitine administra-
tion and pharmacologically mediated reduction in acylcarni-
tine content to test whether the LC acylcarnitine content in
mice muscle could influence glucose metabolism and induce
the development of insulin resistance. To increase the LC
acylcarnitine content, both single-dose and long-term admin-
istration of palmitoylcarnitine (PC), as the most prominent
LC acylcarnitine, were used. We used osmotic minipumps to
continuously deliver PC. A novel compound, 4-[isopropyl(di-
methyl)ammonio]butanoate (IP-GBB), which is a potent
inhibitor of L-carnitine transport by organic cation trans-
porter 2 (OCTN2) [11,12], was used to decrease the acylcar-
nitine content in a model of diet-induced glucose intoler-
ance. Our study is intended to explain the physiological role
of LC acylcarnitines and to link the acceleration of skeletal
muscle insulin resistance to the excessive accumulation of
LC acylcarnitines.
2. Experimental Procedures
2.1. Animals and treatments
A total of 180 male CD-1 (12 weeks old, Harlan Laboratories
BV and Envigo) mice were housed under standard conditions
(21–238C, 12 h light–dark cycle) with unlimited access to food
(R70 diet, Lantm€annen Lantbruk, Sweden) and water. All ani-
mals were adapted to local conditions for 2 weeks before the
start of experiments. The experimental procedures were car-
ried out in accordance with the guidelines of the European
Community, local laws and policies and were approved by the
Latvian Animal Protection Ethical Committee, Food and Veteri-
nary Service, Riga, Latvia. All studies involving animals are
reported in accordance with the ARRIVE guidelines [13,14].
Adult CD-1 mice were used for experiments as a well charac-
terized strain widely used for metabolic studies. In addition,
adult male Wistar rats (n 5 10) were used to characterize gua-
nabenz induced hypoinsulinemia/hyperglycemia state at multi-
ple time points. Animals were randomized according to their
body weight in order to match the age of control and experi-
mental groups. All samples were collected in the morning 9–
11 A.M.
2.2. Single-dose PC administration
PC hydrochloride was synthesized from L-carnitine and palmi-
toyl chloride by a modified protocol (see Supporting Informa-
tion) as described in the literature [15]. To study the effects of
LC acylcarnitines on glucose homeostasis, PC was adminis-
tered intraperitoneally at a dose of 50 mg/kg. In the fasted
state, glucose and insulin levels were measured 60 min after
PC administration. In the fed state, after 30 min of PC adminis-
tration, insulin (0.3 IU/kg) was administered subcutaneously,
and glucose concentrations were measured 60 min after PC
administration. In addition, to ensure a continuous dosing of
PC, osmotic minipumps (ALZETVR , USA) filled with PC (50 mg/
kg/day) were implanted subcutaneously in the mice (n 5 4) for
24 h. In control animals (n 5 4), osmotic minipumps loaded
with saline (vehicle) were implanted. On the day prior to
ALZET minipump implantation, mice were anesthetized using
2% isoflurane dissolved in the mixture of oxygen and nitrous
oxide (50/50, v/v). Fur from the scapular region and nape was
removed using commercially available depilation cream. On
the next day, experimental animals received sodium benzylpe-
nicillin (150 mg/kg i.p.) and tramadol (10 mg/kg i.p.) and were
anesthetized using 2% isoflurane. Transverse 1.5 cm skin inci-
sion was made above shoulder blades and subcutaneous
pocket was formed on the back of the animal. ALZET mini-
pump model 2004 was inserted in the subcutaneous pocket
and skin was closed using 4–0 silk sutures (Ethicon, USA). Glu-
cose tolerance testing and metabolic phenotyping was per-
formed during 24 h after the implantation of minipumps. To
inhibit endogenous insulin release, guanabenz (i.p. 1 mg/kg,
GB), an a2-adrenoreceptor agonist [16], was used after the
single-dose PC (50 mg/kg) administration. In fasted animals,
glucose flux is very limited and GB induces hyperglycemia only
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in fed animals, therefore in our experiment, we administrated
GB in fed mice. Thirty mice were randomly separated into two
experimental groups, GB (n 5 15) and GB 1 PC (n 5 15). To
determine the insulin-dependent effects of PC, insulin (0.3 IU/
kg) was administered subcutaneously 1 h after the intraperito-
neal injection of GB or GB 1 PC.
2.3. Slow-release and long-term PC administration
To determine the effects of the long-term increased availability
of LC acylcarnitines, mice were randomly separated into con-
trol (n 5 10) and PC (n 5 10) groups. To ensure a continuous
and long-term dosing of PC, osmotic minipumps (ALZETVR ,
USA) filled with PC (10 mg/kg/day) were implanted subcutane-
ously in the mice for 28 days. In control animals, osmotic mini-
pumps loaded with saline (vehicle) were implanted. The
osmotic minipump implantation was performed identically as
described above in the single-dose PC administration section.
Sutures were removed on the seventh day after the surgery. At
the end of the 28-day treatment, glucose and insulin tolerance
tests were performed, and biochemical parameters were
measured.
2.4. Pharmacological decrease of LC acylcarnitines
To determine the therapeutic potential of a decreased avail-
ability of LC acylcarnitines on insulin resistance, the pharma-
cological agent IP-GBB at a dose of 10 mg/kg which decreases
acylcarnitine content, was used in the study. Synthesis of IP-
GBB was performed as described by Tars et al. [12]. Thirty
mice were randomly separated into three experimental
groups, R70 Control (n 5 10), HFD (Western RD, Special Diets
Services, UK) (n 5 10), and HFD 1 IP-GBB (n 5 10). At the end
of the 28-day treatment, glucose (1 g/kg) and insulin (0.5 IU/
kg) tolerance tests were performed, and biochemical parame-
ters were measured.
2.5. Cell culture experiments
To assess the effect of PC on insulin secretion in vitro, we used
an insulin-secreting cell line, RIN-5F (ATCCVR Number: CRL-
2058) and determined the insulin concentration in the culture
medium using a Sensitive Rat Insulin RIA kit (Millipore, Biller-
ica) after 1 h of incubation with PC at a dose of either 3 or 10
mM in serum and FA-free DMEM under both basal and hyper-
glycemic conditions, which contained 5.5 and 11 mM glucose,
respectively. To differentiate the PC and palmitic acid-induced
effects on insulin secretion, DC260126, a small-molecule
antagonist of free fatty acid receptor 1 (FFAR1/GPR40), at a
concentration of 5 mM was preincubated 1 h before the addi-
tion of PC at a concentration of 10 mM.
To evaluate the PC-induced effect on Akt phosphorylation,
C2C12 ATCCVR CRL-1772TM) mouse skeletal myoblasts were
differentiated in DMEM containing 2% horse serum for 5 days.
Then, the medium was replaced with serum-free DMEM and
PC at doses of 5 and 10 mM; after an overnight incubation, the
basal or insulin-stimulated (10 nM for 15 min) level of Akt
phosphorylation was determined by a western blot analysis.
The medium was removed, and the cells were lysed in a buffer
containing 100 mM Tris–HCl, pH 7.4, 10 mM EDTA, 5 mM
MgCl2, 1 mM glycerol 3-phosphate, 1 mM NaF, 500 mM
Na3VO4, 1 mM DTT, phosphatase inhibitor cocktail I 1:100
(Alfa Aesar), protease inhibitors (10 lM leupeptin, 1 lM pep-
statin, 1 lM aprotinin, and 100 lM PMSF), and 1% IGEPAL at
48C for 10 min. The lysates were centrifuged at 10,000 rpm for
5 min at 48C. The supernatants were stored at 2808C until
analysis.
2.6. Measurements of glucose uptake and fatty acid
metabolism in vivo
To determine the glucose uptake or FA metabolism (uptake
and oxidation) in vivo, 1 mCi of 2-[1,2-3H]-deoxy-D-glucose
([3H]-DOG, specific activity, 60 Ci/mmol) or 1 mCi [9,10-3H]-pal-
mitate (specific activity, 60 Ci/mmol), respectively, were
administered intravenously to the mice. After 10 min, the mice
were sacrificed by cervical dislocation, and skeletal muscle,
liver and adipose tissue homogenates (1:5, w/v in MilliQ water)
were prepared. To determine the palmitate metabolism in
vivo, samples were treated as previously described [17]. The
contents of [3H]-DOG or [3H]-palmitate in the tissue samples
were determined by a liquid scintillation method.
2.7. Metabolic phenotyping
The PhenoMaster system for mice (TSE, Germany), with auto-
mated food/liquid access control units and an indirect gas calo-
rimetry system, was used to monitor 24 h changes in energy
metabolism. Indirect gas calorimetry was used for the meas-
urements of the animals’ oxygen consumption (VO2) and car-
bon dioxide production (VCO2) to estimate various metabolic
parameters, including the respiratory exchange rate (RER)
and fat and carbohydrate utilization for energy production.
2.8. mRNA isolation and quantitative RT-PCR analysis
Total RNA from muscle tissues was isolated using TRI Reagent
(Sigma, St. Louis, MO) according to the manufacturer’s proto-
col. The first-strand cDNA synthesis was carried out using a
High Capacity cDNA Reverse Transcription Kit (Applied Biosys-
temsTM, Foster City, CA) following the manufacturer’s instruc-
tions. The quantitative RT-PCR analysis of gene expression
was performed by mixing SYBRVR Green Master Mix (Applied
BiosystemsTM), synthesized cDNA, forward and reverse pri-
mers specific for glucose transporter 1 (GLUT1) and 4
(GLUT4), carnitine palmitoyltransferase-1A (CPT-1A) and 21B
(CPT-1B), long-chain fatty acid CoA synthetase (ACSL), pyru-
vate dehydrogenase lipoamide kinase isozyme 4 (PDK4), tumor
necrosis factor a (TNFa), interleukin 1 b (IL1b), inducible nitric
oxide synthase (iNOS), or b-actin and running the reactions on
an Applied Biosystems Prism 7500 instrument according to the
manufacturer’s protocol. The relative expression levels for
each gene were calculated with the DDCt method and normal-
ized to the expression of b-actin. The primer sequences used
for the quantitative RT-PCR analysis are available upon
request.
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Acute PC effects on the concentrations of blood glucose and insulin and 3H-deoxyglucose uptake. The administration of PC
(50 mg/kg i.p. 1 h) increased the muscle long-chain acylcarnitine content (A), the blood glucose concentrations in fasted (B),
and fed (C) mice in vivo, while the administration of insulin (0.3 IU/kg, s.c.) overcame the PC-induced effects on blood glucose
(C). The administration of PC (50 mg/kg/24 h) with osmotic minipumps induced disturbances in glucose tolerance (D) and a
delayed shift of energy production toward glucose oxidation (E). PC (3 and 10 mM 1 h) induced insulin release in insulin-
secreting cell line, RIN-5F, which was not inhibited by an inhibitor of FA targeted GPR40 (FFAR1) receptor (F). The administra-
tion of PC 50 and 100 mg/kg after 1 h induced an increase in insulin release, respectively, in fasted (G) and fed state (H) in
vivo. Guanabenz (GB; 1 mg/kg i.p.) administration significantly reduced plasma insulin concentration (I) and induced a marked
increase in glucose concentration, which was reduced by the administration of insulin (0.3 IU/kg s.c.) (J). The administration of
PC (50 mg/kg i.p.) with GB and insulin markedly diminished the insulin action on blood glucose level (J) and [3H]-DOG uptake
in skeletal muscles (K), while it did not influence the uptake and metabolism of [3H]-palmitate (L). Palmitate metabolism was
determined by measurement of acid soluble species (ACS). Each value represents the mean 6 SEM of 4 (D, E), 5 or 8 (experi-
ments with GB) animals. For A, each value represents the mean 6 SEM of 8 (Fed), 3 (Fed 1 PC), or 5 (fasted) animals.*Signifi-
cantly different from the respective control group, #significantly different from the insulin control group, and $significantly
different from the baseline (Student’s t test or ANOVA following Tukey’s test, P<0.05).
FIG 1
2.9. Western blot analysis of tissue lysates
Hindlimb muscle tissues were homogenized by an Ultra-
TurraxVR homogenizer (IKA, Germany) at a ratio of 1:10 (w/v)
at 48C in a buffer containing 100 mM Tris–HCl, pH 7.4, 10 mM
EDTA, 5 mM MgCl2, 1 mM glycerol 3-phosphate, 1 mM NaF,
and protease inhibitors (10 lM leupeptin, 1 lM pepstatin, 1 lM
aprotinin, and 100 lM PMSF). The PAGE and western blot
analysis of tissue lysates was performed as described previ-
ously [18]. To detect the phosphorylation level of Akt at
Ser473, membranes were incubated with anti-P-Akt (#sc-
7985-R; Santa Cruz Biotechnology, CA, or #4060S; Cell Signal-
ing Technology, Danvers, MA) specific antibodies and the
obtained data were normalized against total Akt (#sc-8312;
Santa Cruz Biotechnology) protein expression. The blots were
developed using chemiluminescence reagents (Millipore). The
western blot images were scanned and then analyzed using
Gel-Pro Analyzer 6.0 software.
2.10. Pyruvate dehydrogenase activity assay
Isolated cardiac mitochondria were used to determine the abil-
ity of PC to inhibit pyruvate dehydrogenase (PDH) a rate limit-
ing enzyme of PDH complex. PC was preincubated with the
isolated mitochondria for 10 min at room temperature. The
activity of PDH was measured spectrophotometrically as previ-
ously described [19].
2.11. Determination of acylcarnitine profile in muscles
Determination of the content of acylcarnitines in the skeletal
muscle tissue samples was performed by the ultra-
performance liquid chromatography-tandem mass
spectrometry (UPLC-MS-MS) as described by Kivilompolo et al.
[20] with some modifications. Waters Acquity UPLC H-Class
chromatograph was coupled to Waters Xevo TQ-S tandem
mass spectrometer. Chromatographic separation was per-
formed on Waters Acquity UPLC BEH Hilic (2.1 3 100 mm, 1.7
mm) column in gradient mode. Solvent A was 10 mM ammo-
nium acetate with 0.2% formic acid in water and solvent B
was acetonitrile. Initial mobile phase composition was 10%
solvent A and was linearly increased to 20% solvent A in 7
min. Total run time with column flush and re-equilibration
was 10 min. Column temperature was 308C and flow rate was
0.5 mL/min. Data acquisition was performed in positive elec-
trospray ionization (ESI1) and multiple reaction monitoring
(MRM) mode. The ion source parameters were as follows:
source temperature 1208C, capillary voltage 2.5 kV, desolva-
tion gas temperature 6008C, and desolvation and cone gas flow
800 L/h and 150 L/h, respectively. The MRM transitions with
cone and collision energy values are presented in Supporting
Information Table S1. The sample extraction was performed
as described previously [21,22]. The concentrations of acylcar-
nitines were measured against a nine-point standard curve of
C4–C18 and C2–C3 acylcarnitine in a range 0.01–20 nM and
0.2–200 nM in analytical sample, respectively. The concentra-
tion of acylcarnitine was expressed nmol per mg of wet
weight.
2.12. Glucose and insulin tolerance tests
To perform the glucose tolerance test, the mice were fasted
overnight. Then, a glucose solution (0.5 or 1 g/kg of body
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were drawn from the tail vein at 0 (fasting), 15, 30, 60, 120,
180, and 240 min. To perform the insulin tolerance test, an
insulin solution (0.3 or 0.5 IU/kg of body weight) was adminis-
tered subcutaneously to the fed mice, and blood samples were
drawn from the tail vein at 0 (fed), 30, 60, 120, and 240 min.
The blood glucose concentration was measured using a Medi-
Sense Optium Xceed blood glucose meter and strips.
2.13. Determination of biochemical parameters in
plasma
For biochemical measurements, blood samples were collected
from the tail vein in heparin-containing tubes. To obtain
plasma, the samples were centrifuged at 1,000g for 10 min at
48C. All samples were stored at 2808C until analysis. The
plasma glucose, triglyceride, and insulin concentrations were
determined using kits from Instrumentation Laboratory, a Sen-
sitive Rat Insulin RIA kit and a Rat/Mouse Insulin ELISA kit
(Millipore). The lactate level was measured in the samples using
an enzymatic kit from Roche Diagnostics (Mannheim, Germany).
The concentration of free FAs was measured using commer-
cially available enzymatic kit from Wako (Neuss, Germany).
2.14. Statistical analysis
All data are expressed as the mean 6 standard error of the
mean (SEM). For the statistical analyses, Student’s t test or a
one-way ANOVA with Tukey’s post-test were used. P values
less than 0.05 were considered to be statistically significant.
The statistical calculations were performed using Prism 3.0
software (GraphPad, San Diego, California).
3. Results
3.1. Effects of single-dose PC administration on
glucose metabolism
Acylcarnitines are intermediates of FA metabolism, but they
constitute only a small fraction of total FA pool. Administration
of PC at doses of 10–50 mg/kg/24 h corresponds to only 0.3–
1.5% of the total body FA turnover suggesting that administra-
tion of PC does not significantly influence FA metabolism. In
addition, PC transport in the skeletal muscles is limited and
administration of PC at a dose of 50 mg/kg induced only a
threefold increase in the intramuscular content of LC acylcar-
nitines (Fig. 1A and Supporting Information Table S2). In
comparison, after overnight fasting skeletal muscle LC acylcar-
nitine content was fivefold higher than LC acylcarnitine
content in fed state (Fig. 1A, Supporting Information Table
S2). Thus, PC treatment induced effect on muscle LC acylcarni-
tine content is similar to short-term fasting.
The single-dose administration of PC induced a significant
increase in the blood glucose concentrations of fasted (Fig. 1B)
and fed (Fig. 1C) mice. The administration of insulin signifi-
cantly reduced blood glucose with and without the coadminis-
tration of PC. This additional increase in insulin concentration
was able to decrease the PC-induced effect on blood glucose,
suggesting that higher concentrations of insulin can overcome
PC-induced effects on glucose metabolism.
To test the 24-h effect of PC administration on glucose tol-
erance and energy metabolism balance in mice, PC (50 mg/kg/
day) was administered by slow-release minipumps. In the glu-
cose tolerance test, we observed a significantly higher increase
in blood glucose in the PC group mice (Fig. 1D). In addition,
the RER was decreased in mice with PC (Fig. 1E). Thus,
increased PC concentration delays the glucose metabolism
transition from the fed to fasted state.
Taking into account the LC acylcarnitine-induced effects
on insulin secretion observed in an in vitro model [23], we
determined the effect of PC on insulin release in vitro and in
vivo. According to the study by Soni et al., insulin-stimulating
action depends on intracellular LC acylcarnitine production
and transport rate into cells [23]. We also found that 3 and 10
mM concentrations of PC were sufficient to increase intracellu-
lar LC acylcarnitine contents within 1 h and to stimulate insu-
lin release from RIN-5F cells (Fig. 1F). To evaluate whether PC
acts by a different mechanism than FA, we incubated PC in
the presence of DC260126, an inhibitor of FA targeted GPR40
(FFAR1) receptor in b-cells. The effect of 10 mM PC was not
inhibited by DC260126 (Fig. 1F) indicating that observed PC
effect on insulin release was not induced by palmitate action.
To confirm this effect in vivo, we performed a bolus adminis-
tration of PC in fasted mice. The administration of PC induced
a significant fivefold increase in insulin concentration (Fig.
1G). Up to a twofold increase in insulin concentration was also
observed after PC administration in fed mice (Fig. 1H). Overall,
PC potentiates glucose-stimulated insulin release, thus sug-
gesting that the LC acylcarnitine effect is important for the
physiological transition from the fasted to fed state and that it
induces hyperinsulinemia in the case of diabetes.
Serious drawback of insulin clamp method in mice is neces-
sity to administrate general anesthetics which induce marked
Mechanisms of PC action. PC does not influence pyruvate dehydrogenase (PDH) activity in isolated mitochondria (A). In C2C12
cells, the basal phospho-Akt level is very low, while insulin-stimulated Akt phosphorylation is pronounced, and PC at a concen-
tration of 5 and 10 mM dose-dependently decreased the level of phospho-Akt (B). Insulin at 100 nM overcame PC-induced effect
on Akt phosphorylation (B). The administration of PC (50 mg/kg i.p. 1 h) decreased the level of phospho-Akt in fed mouse mus-
cle in vivo, while the administration of insulin (0.3 IU/kg s.c.) overcame the PC-induced effect (C). Significant changes were
observed in gene expression between the fed and fasted states, while PC administration (100 mg/kg i.p. 1 h) did not influence
the expression of selected genes of energy metabolism (D, E) and inflammation (F). Each value represents the mean 6 SEM of
five animals or three to five independent measurements of PDH activity. *Significantly different from the control group and
#significantly different from the PC group (ANOVA following Tukey’s test, P<0.05). $Significantly different from the fed control
group (ANOVA following Tukey’s test, P<0.05).
FIG 2
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insulin resistance [24]. Therefore, taking into account the PC
effect on insulin release, we used a novel experimental method
suitable for the evaluation of both insulin-dependent and
insulin-independent glucose homeostasis in vivo. To study the
insulin-independent PC effects on plasma glucose, we adminis-
tered the a2-adrenoreceptor agonist GB, which inhibits insulin
release [16,25]. For the evaluation of insulin-dependent effects,
GB administration was followed by insulin administration. In
the fed control mice, administration of GB caused hypoinsuline-
mia (Fig. 1I) and induced a marked increase in plasma glucose
from 8.6 mM up to 17.7 mM, while the subsequent insulin
administration increased insulin concentration (Fig. 1I) and sig-
nificantly decreased the glucose concentration back to the initial
level (Fig. 1J). The administration of PC in combination with GB
induced increase in the plasma glucose concentration to 3 mM
higher than that in the GB group. PC also significantly dimin-
ished the insulin-induced blood glucose lowering effect (Fig. 1J).
Thus, the blood glucose concentration in the PC group remained
5 mM higher than that in the control mice. In rats the PC-
induced effect on insulin-dependent blood glucose utilization
was even more pronounced and glucose concentration did not
decrease after administration of insulin (Supporting Information
Fig. S1). These effects could be explained by a PC-induced sig-
nificant decrease in insulin-stimulated [3H]-DOG uptake in
skeletal muscles (Fig. 1K). Importantly, the PC effect on blood
glucose is partially masked by the significantly stimulated [3H]-
DOG uptake in liver and adipose tissue (Fig. 1K). In addition, no
effect of PC on [3H]-palmitate uptake and metabolism was
observed (Fig. 1L). Overall, the PC administration limits insulin-
related glucose uptake in muscles.
3.2. Mechanisms of PC action
In previous studies, the inhibition of the PDH was suggested as
a possible mechanism of PC action [9,26]. In this study, we did
not observe any significant PC effect on PDH activity (Fig. 2A).
The overnight incubation of PC (5 or 10 mM) with or without
insulin (10 nM for 15 min) decreased Akt Ser-473 phosphoryl-
ation in the C2C12 muscle cell line (Fig. 2B). The increase in
insulin concentration overcomes the PC-induced inhibition of
Akt phosphorylation (Fig. 2B). In the C2C12 cell line, incuba-
tion with PC in the presence of 100 nM insulin did not influ-
ence the phospho-Akt Ser-473 levels (Fig. 2B). A similar effect
on Akt phosphorylation was observed in mouse muscles after
a single administration of PC (50 mg/kg) (Fig. 2C). Thus, PC
induces the inhibition of Akt phosphorylation, while increases
in insulin concentration up to a certain level can overcome the
PC-induced effects on insulin signaling.
It would be expected that administered PC competes with
FA for uptake and oxidation in mitochondria. However, PC
does not influence the FA uptake and metabolism rate in skel-
etal muscle tissue (Fig. 1L). Taking into account that FA
metabolism was not influenced by PC, the inhibition of glucose
metabolism is also not related to the Randle cycle and exces-
sive mitochondrial oxidation of PC. In addition, PC administra-
tion does not influence PPARa activity (data not shown) and
the expression of genes involved in muscle glucose transport
and FA metabolism (Figs. 2D and 2E) and genes related to
inflammation (Fig. 2F). We observed significant differences in
gene expression between the fed and fasted states; however,
PC did not influence FA metabolism-related and inflammatory
gene expression in either state. Overall, the inhibitory effect on
Akt phosphorylation and related insulin signaling is an impor-
tant mechanism of PC action.
3.3. Effects induced by the long-term, slow-release
administration of palmitoylcarnitine
To ensure the long-term administration of PC, we used slow-
release osmotic minipumps (ALZETVR , USA). This experimental
setup ensured a permanent increase in LC acylcarnitine content
in muscles for 28 days. In the control mice, minipumps loaded
with saline (vehicle) were implanted. PC administration at a
dose of 10 mg/kg/day in muscles induced a substantial twofold
increase in the content of PC and total LC acylcarnitine content
(Figs. 3A and 3B, Supporting Information Table S3). Increase in
content of other LC acylcarnitines could be explained by the
inhibitory action of PC on the insulin signaling pathway, which
in turn limits the Akt-mediated inhibition of CPT-1 activity. In
addition, PC competed for metabolism in mitochondria with
other LC acylcarnitines and induced increases in their content.
A long-term increase in LC acylcarnitine content resulted in
impaired glucose tolerance (Fig. 3C). The AUC calculated from
the glucose tolerance test data in the PC group was significantly
increased by 30%. PC administration by minipumps completely
blocked the insulin-induced blood glucose lowering effect in the
insulin tolerance test (Fig. 3D). In the control animals, insulin
administration induced an approximate 3 mM decrease in blood
glucose concentration, while in the PC group, blood glucose was
not changed during the 4 h test period. In PC-treated mice,
plasma glucose concentrations were similar to that of the con-
trol mice; however, it is likely that glucose concentrations were
not affected due to the 2.8-fold increase in insulin concentration
in the fed state (Fig. 3E). In addition, the PC-induced increase in
lactate concentration suggests incomplete glucose oxidation
(Fig. 3F). In contrast, PC administration did not influence
plasma triglyceride and FA concentrations (Figs. 3G and 3H). PC
administration with slow-release capsule did not change mice
weight gain (Fig. 3I). Thus, the PC-induced glucose intolerance
is not related to changes in FA flux. Overall, the long-term
increase in LC acylcarnitine content induced insulin resistance
and hyperinsulinemia.
3.4. Effect induced by the administration of an OCTN2
inhibitor in HFD-fed mice
To confirm our hypothesis that a decrease in LC acylcarnitine
content could improve insulin sensitivity in insulin-resistant
individuals, we used a high-fat diet (HFD)-induced insulin-
resistance model and a novel inhibitor of OCTN2, IP-GBB. In
HFD-fed mice, the muscle content of short-, medium- and LC
acylcarnitines was similar to that of control mice (Fig. 4A, Sup-
porting Information Table S4), while a 28-day treatment with
IP-GBB significantly decreased the LC acylcarnitine content
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Effects induced by the long-term, slow-release administration of palmitoylcarnitine. The slow-release administration of PC
(10 mg/kg/day) for 28 days induced a marked increase in the content of all long-chain (LC) acylcarnitines (A) and the total con-
tent of LC acylcarnitines (B) in skeletal muscles in fed state. The changes in muscle acylcarnitine content induced disturbances
in glucose tolerance (C) and reduced insulin sensitivity (D). PC induced a marked increase in insulin concentration in the fed
state (E). The lactate concentration was increased in both the fed and fasted states (F), while PC did not influence triglyceride
(G) and FA concentrations (H) and body weight (I). Each value represents the mean 6 SEM of 10 animals. *Significantly differ-
ent from the respective control group (Student’s t test or ANOVA following Tukey’s test, P<0.05).
FIG 3
from 15.2 to 2.6 nmol/g. Similarly, IP-GBB treatment decreased
the content of short- and medium-chain acylcarnitines.
The HFD induced significantly increased weight gain and
marked glucose intolerance (Figs. 4B and 4C). In HFD-fed mice,
the glucose concentrations at 15, 30, and 60 min after glucose
administration were 5–7 mM higher compared to those of the
control group. The long-term pharmacological decrease in acyl-
carnitine content prevented the HFD-induced disturbances in
glucose tolerance (Fig. 4C). Thus, 15 and 30 min after glucose
administration, the glucose concentrations in the IP-GBB-
treated mice were similar to those of the control group. In
addition, the decrease in acylcarnitine content reduced hyper-
glycemia in the fed state (Fig. 4D). Moreover, IP-GBB treatment
stimulated complete glucose oxidation and reduced the lactate
concentration in the fed and fasted states by 2.4 and 1.3 mM,
respectively (Fig. 4E). IP-GBB treatment decreased the HFD-
induced increase in insulin concentration in the fed state (Fig.
4F). Overall, although the content of LC acylcarnitines in HFD-
fed mice was not increased, the pharmacological decrease of LC
acylcarnitine content improved glucose tolerance.
4. Discussion
In this study, we show that LC acylcarnitines influence glucose
metabolism in vivo and therefore are important players in the
physiological regulation of energy metabolism. Moreover, the
Effect induced by the administration of the OCTN2 inhibitor IP-GBB in HFD-fed mice. IP-GBB at a dose of 10 mg/kg was adminis-
tered for 28 days to HFD-fed mice. IP-GBB induced a significant decrease in acylcarnitine content in muscles (A). HFD feeding
increased weight gain while IP-GBB did not significantly influenced weight gain (B). The administration of IP-GBB prevented HDF-
induced impairments in glucose tolerance (C) and reduced the HFD-induced increase in fed state glucose concentration (D). The
lactate (E) and insulin (F) concentrations in the fed state were not significantly increased in HFD-fed mice. Each value represents
the mean 6 SEM of 10 animals. *Significantly different from the HFD group (ANOVA following Tukey’s test, P<0.05).
FIG 4
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accumulation of LC acylcarnitines during the fed state can
accelerate diabetes progression by the simultaneous induction
of insulin resistance and insulin release in vivo. A single-dose
administration of PC in mice inhibits Akt phosphorylation in
muscles and the downstream signaling pathways involved in
glucose uptake. The long-term administration of PC induces
insulin resistance, hyperinsulinemia and disturbances in glu-
cose tolerance. In the model of lipid overload induced by a
HFD, a decrease in LC acylcarnitine content restores glucose
tolerance and insulin sensitivity and reduces hyperinsulinemia.
In previous studies, we hypothesized that LC acylcarnitines
are not only markers for incomplete FA oxidation but also
active FA metabolites involved in the regulation of energy
metabolism [9,27]. In this study, we confirm this hypothesis
through our results indicating that the acute and chronic
administration of PC in vivo limits insulin signaling-induced
effects and insulin-related glucose uptake in muscles. Accord-
ing to our results, the mechanism behind LC acylcarnitine
action in muscles is the inhibition of Akt phosphorylation and
the subsequent inhibition of downstream signaling. This is in
line with previous studies in C2C12 myotubes [4,5]. Interest-
ingly, an increased concentration of insulin can overcome the
LC acylcarnitine-induced effects and stimulate Akt phosphoryl-
ation to the appropriate level. This explains how in the fed
state in response to glucose, increased concentrations of insu-
lin can overcome the inhibitory effects of high LC acylcarnitine
content [8,28]. In addition, to support the transition from the
fasted to fed state and overcome transient intramuscular insu-
lin insensitivity, LC acylcarnitines facilitate insulin release.
In the fasted state, the low level of insulin is unable to
inhibit LC acylcarnitine production, and the high LC acylcarni-
tine content continuously inhibits the Akt pathway. As a result,
glucose uptake and metabolism is limited, while LC acylcarni-
tine synthesis by CPT-1 and subsequent FA oxidation increase.
Therefore, in starved individuals, the intracellular content of
LC acylcarnitines is higher than in the fasted state [28]. In our
study, both a bolus and long-term administration of PC
increased the content of C18 acylcarnitines, suggesting that a
high LC acylcarnitine content blocks the insulin-induced CPT-1
inhibition and stimulates an even higher increase in LC acyl-
carnitine content. Many studies indicate that acylcarnitine
accumulation is a result of incomplete FA oxidation [1,2,5,29].
Indeed, during ischemia or heart failure, acylcarnitines accu-
mulate in mitochondria because of a transient or permanent
inhibition of FA-dependent oxidative phosphorylation in mito-
chondria [10,30,31]. However, our results indicate that in cer-
tain conditions such as the fasted state, the physiologically
important LC acylcarnitine accumulation is a result of their
CPT-1-driven overproduction coupled to a high FA oxidation
rate. Overall, LC acylcarnitines, as inhibitors of Akt phospho-
rylation, are active participants in an intercellular feedback
mechanism of insulin signaling and are a substantial part of
the energy metabolism regulation program (Figs. 5A and 5B).
In healthy subjects in the fed state, to inhibit FA metabo-
lism and facilitate glucose metabolism the increased concen-
tration of insulin inhibits LC acylcarnitine production via the
increased tissue content of malonyl-CoA [1,28]. That occurs

















































Physiological and pathological actions of long-chain acylcarnitines: implications for the development of insulin resistance. (A)
In the fasted state, the low level of insulin is unable to inhibit acylcarnitine production, and the high acylcarnitine content con-
tinuously inhibits the phospho-Akt pathway and glucose uptake and metabolism. (B) Glucose in the fed state stimulates insulin
release, which overcomes the acylcarnitine-induced effects on insulin signaling and reduces acylcarnitine production. Acylcar-
nitines in the presence of glucose facilitate insulin release to stimulate the transition from the fasted to fed state. (C) In the
case of insulin resistance, insulin cannot effectively decrease acylcarnitine production in the fed state. This results in the accu-
mulation of acylcarnitines, the continuous inhibition of Akt phosphorylation and subsequent disturbances in glucose uptake
and metabolism. Thus, the accumulation of acylcarnitines during the fed state limits metabolic flexibility and accelerates hyper-
glycemia and hyperinsulinemia. The red arrows indicate whether the concentration is relatively high (") or low (#).
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kinase (AMPK) activity, which results in the stimulation of
acetyl-CoA carboxylase (ACC; synthesis of malonyl-CoA) and
inhibition of malonyl-CoA decarboxylase (MCD; degradation of
malonyl-CoA) [32,33]. The inability of insulin to inhibit LC acyl-
carnitine production in the fed state induces disturbances in
glucose uptake and metabolism. In the early stage of insulin
resistance, hyperinsulinemia can compensate for insulin resist-
ance and also overcome the LC acylcarnitine-induced effects.
In the later stages of the disease, insulin resistance leads to
the inability to inhibit LC acylcarnitine production and is
accompanied by increased concentrations of LC acylcarnitines,
which continuously inhibit the Akt-mediated signaling pathway
and further stimulate the progression of glucose intolerance.
Thus, the accumulation of LC acylcarnitines can accelerate the
progression of insulin resistance (Fig. 5C).
Acylcarnitine accumulation has been detected in various
models of advanced diabetes. Overall, it has been shown that
the accumulation of LC acylcarnitines is not related to mito-
chondria dysfunction and usually reflects a higher FA oxida-
tion rate in animal muscle and heart tissues [4,10,34,35]. In
this study, at the early stage of insulin resistance and glucose
intolerance induced by a high-fat diet, the muscle LC acylcar-
nitine content, similar to the free FA and blood glucose con-
centrations, was not significantly increased. This is an obvious
effect of hyperinsulinemia, which at the early stages of insulin
resistance can compensate for the inability of the muscle tis-
sue to respond to lower insulin concentrations. At this stage of
the disease, insulin resistance can be detected only by
increased insulin concentrations and changes in the glucose
and insulin tolerance or clamp tests. Similar to glucose and
other markers, the LC acylcarnitine content is not markedly
elevated at the early stages of insulin resistance but rather is a
feature of severe diabetes.
The beneficial effects of genetically and pharmacologically
induced LC acylcarnitine decreases have been demonstrated in
models of insulin resistance. The limited production of acylcar-
nitines and oxidation of FA in MCD–/– knockout mice resulted
in a remarkable protection against HFD-induced metabolic
perturbations [4,34]. In addition, it was demonstrated that
treatment with the CPT-1 inhibitor oxfenicine resulted in
improved whole-body glucose tolerance and insulin sensitivity
in the high-fat diet-induced insulin-resistance model [36].
Recently, a decrease in L-carnitine content was shown to
decrease LC acylcarnitine content and in turn reduced circu-
lating glucose and insulin concentrations [10]. The decrease in
the LC acylcarnitine production has a more pronounced
insulin-sensitizing effect at the early stage of insulin resistance
when the LC acylcarnitine content is not increased. In con-
trast, a somewhat limited beneficial effect of the LC acylcarni-
tine decrease was observed in db/db mice, suggesting that the
efficacy of this approach is limited in individuals with severely
impaired insulin signaling either upstream or downstream of
the Akt pathway. An important advantage of LC acylcarnitine-
decreasing treatment is that it could be effectively combined
with other treatments and lifestyle changes to achieve syner-
gistic effects [10,37].
In this study, while the LC acylcarnitine content was not
increased in HFD-treated mice, the pharmacologically induced
decrease of LC acylcarnitines markedly improved glucose
tolerance. The labeled [3H]-DOG in vivo uptake results (data
not shown) suggest that a 4-week HFD treatment initially indu-
ces insulin resistance in adipose tissue but not in muscles.
Therefore, muscle LC acylcarnitine accumulation in the fed
state of HFD-fed mice was not observed. Nevertheless, a
pharmacological-mediated decrease in LC acylcarnitine con-
tent improved muscle insulin sensitivity, which compensated
for the adipose tissue insulin resistance and thus improved the
overall glucose tolerance and prevented fed-state hyperinsulin-
emia. This confirms that LC acylcarnitines at physiological
concentrations are regulators of energy metabolism and that
by decreasing the physiological levels of LC acylcarnitines, it is
possible to improve muscle insulin sensitivity.
In conclusion, taking into account the importance of mus-
cle metabolic flexibility and the ability to switch between fed
and fasted states, LC acylcarnitines play a role in the regula-
tion of energy metabolism. Our results link the development of
skeletal muscle insulin resistance to the excessive accumula-
tion of LC acylcarnitines and, moreover, suggest that acylcar-
nitines could induce insulin resistance independently of FA
content and oxidation rate. These findings suggest that acyl-
carnitine decrease could be an effective pharmacologic strat-
egy to prevent the acceleration of diabetes.
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